HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laron, Z Search for Related Content PubMed PubMed Citation Articles by Laron, Z

Insulin-like growth factor 1 (IGF-1): a growth hormone

Endocrinology and Diabetes Research Unit, WHO Collaborating Center for the Study of Diabetes in Youth, Schneider Children's Medical Center, Tel Aviv University, 14 Kaplan Street, Petah Tikva 49202, Tel Aviv, Israel

Correspondence: Professor Laron laronz{at}clalit.org.il

Aim—To contribute to the debate about whether growth hormone (GH) and insulin-like growth factor 1 (IGF-1) act independently on the growth process.

Methods—To describe growth in human and animal models of isolated IGF-1 deficiency (IGHD), such as in Laron syndrome (LS; primary IGF-1 deficiency and GH resistance) and IGF-1 gene or GH receptor gene knockout (KO) mice.

Results—Since the description of LS in 1966, 51 patients were followed, many since infancy. Newborns with LS are shorter (42–47 cm) than healthy babies (49–52 cm), suggesting that IGF-1 has some influence on intrauterine growth. Newborn mice with IGF-1 gene KO are 30% smaller. The postnatal growth rate of patients with LS is very slow, the distance from the lowest normal centile increasing progressively. If untreated, the final height is 100–136 cm for female and 109–138 cm for male patients. They have acromicia, organomicria including the brain, heart, gonads, genitalia, and retardation of skeletal maturation. The availability of biosynthetic IGF-1 since 1988 has enabled it to be administered to children with LS. It accelerated linear growth rates to 8–9 cm in the first year of treatment, compared with 10–12 cm/year during GH treatment of IGHD. The growth rate in following years was 5–6.5 cm/year.

Conclusion—IGF-1 is an important growth hormone, mediating the protein anabolic and linear growth promoting effect of pituitary GH. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.

Key Words: insulin-like growth factor I • growth hormones • Laron syndrome • growth

This article has been cited by other articles:

				V. A A van Houten, D. O Mook-Kanamori, L. van Osch-Gevers, E. A P Steegers, A. Hofman, H. A Moll, C. M van Duijn, W. A Helbing, A. C S Hokken-Koelega, and V. W V Jaddoe A variant of the IGF-I gene is associated with blood pressure but not with left heart dimensions at the age of 2 years: the Generation R Study Eur. J. Endocrinol., September 1, 2008; 159(3): 209 - 216. [Abstract] [Full Text] [PDF]

				K. K. de Ostrovich, I. Lambertz, J. K. L. Colby, J. Tian, J. E. Rundhaug, D. Johnston, C. J. Conti, J. DiGiovanni, and R. Fuchs-Young Paracrine Overexpression of Insulin-Like Growth Factor-1 Enhances Mammary Tumorigenesis in Vivo Am. J. Pathol., September 1, 2008; 173(3): 824 - 834. [Abstract] [Full Text] [PDF]

				T. Molina-Munoz, M. T. Romero-Avila, and J. A. Garcia-Sainz Insulin-Like Growth Factor-I Induces {alpha}1B-Adrenergic Receptor Phosphorylation through Gss{gamma} and Epidermal Growth Factor Receptor Transactivation Mol. Endocrinol., November 1, 2006; 20(11): 2773 - 2783. [Abstract] [Full Text] [PDF]

				Y. Yu, A. J. Kastin, and W. Pan Reciprocal Interactions of Insulin and Insulin-Like Growth Factor I in Receptor-Mediated Transport across the Blood-Brain Barrier Endocrinology, June 1, 2006; 147(6): 2611 - 2615. [Abstract] [Full Text] [PDF]

				K. A Slot, J. Kastelijn, A. Bachelot, P. A Kelly, N. Binart, and K. J Teerds Reduced recruitment and survival of primordial and growing follicles in GH receptor-deficient mice. Reproduction, March 1, 2006; 131(3): 525 - 532. [Abstract] [Full Text] [PDF]

				E. V. Tchetina, J. Antoniou, M. Tanzer, D. J. Zukor, and A. R. Poole Transforming Growth Factor-{beta}2 Suppresses Collagen Cleavage in Cultured Human Osteoarthritic Cartilage, Reduces Expression of Genes Associated with Chondrocyte Hypertrophy and Degradation, and Increases Prostaglandin E2 Production Am. J. Pathol., January 1, 2006; 168(1): 131 - 140. [Abstract] [Full Text] [PDF]

				S. J. Freedland, W. J. Aronson, B. Trock, P. Cohen, C. J. Kane, C. L. Amling, J. C. Presti Jr., M. K. Terris, and for the Shared Equal Access Regional Cancer Hospit Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy Clin. Cancer Res., November 1, 2005; 11(21): 7735 - 7742. [Abstract] [Full Text] [PDF]

				T. Shimoaka, S. Kamekura, H. Chikuda, K. Hoshi, U.-i. Chung, T. Akune, Z. Maruyama, T. Komori, M. Matsumoto, W. Ogawa, et al. Impairment of Bone Healing by Insulin Receptor Substrate-1 Deficiency J. Biol. Chem., April 9, 2004; 279(15): 15314 - 15322. [Abstract] [Full Text] [PDF]

				A. Skalkidou, E. Petridou, E. Papathoma, H. Salvanos, S. Kedikoglou, G. Chrousos, and D. Trichopoulos Determinants and Consequences of Major Insulin-like Growth Factor Components among Full-Term Healthy Neonates Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 860 - 865. [Abstract] [Full Text] [PDF]

				P. A. Lee, J. W. Kendig, and J. R. Kerrigan Persistent Short Stature, Other Potential Outcomes, and the Effect of Growth Hormone Treatment in Children Who Are Born Small for Gestational Age Pediatrics, July 1, 2003; 112(1): 150 - 162. [Full Text] [PDF]